A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)
A Clinical Study of the Ultrasound Renal Denervation System (PRDS-001) in Patients With Hypertension
Sponsor: Otsuka Medical Devices Co., Ltd. Japan
This observational or N/A phase trial investigates Cardiovascular Diseases and Hypertension and is currently ongoing. Otsuka Medical Devices Co., Ltd. Japan leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Apr 16, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: NA → None
-
Sep 2025 — Apr 2026 [monthly]
Recruiting NA
-
Aug 2025 — Sep 2025 [monthly]
Recruiting NA
-
Nov 2024 — Aug 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jul 2022 — Apr 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
To compare the antihypertensive effect of renal denervation with the Paradise™ system with that of a sham procedure in hypertensive patients receiving two antihypertensive drugs at the time of consent, and treated with a duo combination antihypertensive pill.
Contact Information
- Otsuka Medical Devices Co., Ltd. Japan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Chikushino-shi, Japan , Chiyoda-ku, Japan , Cyuo-ku, Japan , Fukuoka, Japan , Fukuoka, Japan , Hachioji-shi, Japan , Hamamatsu, Japan , Hirosaki-shi, Japan , Hiroshima, Japan , Iwaki, Japan and 41 more locations